The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...
Respondr TNF is a proprietary test that uses objective evidence to predict an individual patient's likelihood of response to infliximab, adalimumab or their biosimilars prior to initiation of therapy.
SAN DIEGO, March 28, 2017 /PRNewswire/ -- Prometheus Laboratories Inc.—a Nestlé Health Science company—announces the launch of IBcause™, an all-in-one convenient test that evaluates a unique ...
The Supreme Court unanimously tossed out medical patent claims for Prometheus Laboratories on Tuesday for a test that could help doctors set drug doses for autoimmune diseases like Crohn's disease, a ...
The MarketWatch News Department was not involved in the creation of this content. New Therapeutic Drug Monitoring Test for Interleukin--23 Inhibitor SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback